SCHEMBL1345641

SCHEMBL1345641

O=C(COc1ccccc1)CP(=O)(O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.57
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
ALPL P05186 1/20 0.50
ALPI P09923 1/20 0.50
ALPG P10696 1/20 0.50
HPGD P15428 1/20 0.49
GAA P10253 1/20 0.47
ALDH1A1 P00352 2/20 0.45
TSHR P16473 1/20 0.45
MAPK10 P53779 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 1/20 0.45
LMNA P02545 1/20 0.45
PLA2G4B P0C869 1/20 0.45
HTT P42858 1/20 0.45
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16383050 0.85 ALOX15 (0.57) ALOX15CYP2C9CYP2C19KMT2AMEN1
SCHEMBL3898377 0.82 ALOX15 (0.74) ALOX15KMT2AMEN1ALPLALPI
SCHEMBL244446 0.81 ALOX15 (0.52) ALOX15CYP2C9CYP2C19KMT2AMEN1
SCHEMBL11031303 0.80 KMT2A (0.57) KMT2AMEN1GAAALDH1A1RAB9A
SCHEMBL6136246 0.80 WDR5 (0.53) GAAALDH1A1NPC1RAB9ALMNA
SCHEMBL4939704 0.80 ALOX15 (0.47) ALOX15CYP2C9CYP2C19KMT2AMEN1
SCHEMBL11285014 0.80 ALOX15 (0.55) ALOX15CYP2C9CYP2C19KMT2AMEN1
SCHEMBL9303147 0.80 ALOX15 (0.50) ALOX15CYP2C9CYP2C19KMT2AMEN1
SCHEMBL16601102 0.78 ALOX15 (0.49) ALOX15CYP2C9CYP2C19KMT2AMEN1
SCHEMBL15396047 0.78 ALOX15 (0.68) ALOX15KMT2AMEN1ALPLALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2545583-B1 METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS VERSUM MAT US LLC (US) 2020-05-13 EP claimed
US-20150011755-A1 AMINE SALTS OF PROSTAGLANDIN ANALOGS DR. REDDYS LABORATORIES LIMITED (IN) 2015-01-08 US claimed
EP-2812314-A1 AMINE SALTS OF PROSTAGLANDIN ANALOGS Dr. Reddy's Laboratories Ltd. (IN) 2014-12-17 EP claimed
US-8906774-B2 Methods and compositions for doping silicon substrates with molecular monolayers DYNALOY, LLC (US) 2014-12-09 US claimed
WO-2013118058-A1 AMINE SALTS OF PROSTAGLANDIN ANALOGS DR.REDDYS LABORATORIES LIMITED (IN) 2013-08-15 WO claimed
EP-2545583-A1 METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS Dynaloy, LLC (US) 2013-01-16 EP claimed
EP-2545583-B1 METHODS AND COMPOSITIONS FOR DOPING SILICON SUBSTRATES WITH MOLECULAR MONOLAYERS VERSUM MAT US LLC (US) 2020-05-13 EP disclosed
US-10103401-B2 Polymer electrolyte composition and polymer electrolyte membrane, polymer electrolyte membrane with catalyst layer, membrane electrode assembly, and polymer electrolyte fuel cell each using the same TORAY INDUSTRIES, INC. (JP) 2018-10-16 US disclosed
EP-3131145-B1 POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME TORAY INDUSTRIES (JP) 2018-09-05 EP disclosed
US-20170125832-A1 POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL EACH USING THE SAME TORAY INDUSTRIES, INC. (JP) 2017-05-04 US disclosed
EP-3131145-A1 POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME Toray Industries, Inc. (JP) 2017-02-15 EP disclosed
EP-2669280-B1 BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES ONO PHARMACEUTICAL CO (JP) 2016-04-27 EP disclosed
US-9150537-B2 Bicyclic compound and use thereof for medical purposes ONO PHARMACEUTICAL CO., LTD. (JP) 2015-10-06 US disclosed
US-4116988-A 16-Phenoxy prostaglandin E1 analogs THE UPJOHN COMPANY (US) 1978-09-26 US disclosed
US-4116989-A 16-Phenoxy prostaglandin F1α analogs THE UPJOHN COMPANY (US) 1978-09-26 US disclosed
US-4087616-A 16-Phenoxy prostaglandin A2 analogs THE UPJOHN COMPANY (US) 1978-05-02 US disclosed
US-4087604-A Substituted ω-pentanorprostaglandins PFIZER INC. (US) 1978-05-02 US disclosed
US-4065472-A TISSUE SPECIFICITY PFIZER INC. (US) 1977-12-27 US disclosed
US-4024179-A Substituted ω-pentanorprostaglandins PFIZER INC. (US) 1977-05-17 US disclosed
US-3931279-A 5-Oxa prostaglandin F2.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011755-A1 AMINE SALTS OF PROSTAGLANDIN ANALOGS PTGIS, PTGER1, PTGER2 ALOX15 81/4885CYP2C9 772/4885CYP2C19 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.